Other Species / Isoforms
  UBE2J1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y5-p
___METRyNLksPAV
0 62
UBE2J1 (human) ___METRyNLksPAV Y5-p
UBE2J1 (mouse) ___METRyNLKsPAV Y5-p
UBE2J1 (rat) ___METRyNLKSPAV Y5-p
UBE2J1 (cow) ___LLTRYLIRSVSV Y5
K8-ac
METRyNLksPAVKRL
0 1
UBE2J1 (human) METRyNLksPAVKRL K8-ac
UBE2J1 (mouse) METRyNLKsPAVKRL K8
UBE2J1 (rat) METRyNLKSPAVKRL K8
UBE2J1 (cow) LLTRYLIRSVSVKRL R8
K8-ub
METRyNLksPAVKRL
0 1
UBE2J1 (human) METRyNLksPAVKRL K8-ub
UBE2J1 (mouse) METRyNLKsPAVKRL K8
UBE2J1 (rat) METRyNLKSPAVKRL K8
UBE2J1 (cow) under review -
S9-p
ETRyNLksPAVKRLM
0 7
UBE2J1 (human) ETRyNLksPAVKRLM S9-p
UBE2J1 (mouse) ETRyNLKsPAVKRLM S9-p
UBE2J1 (rat) ETRyNLKSPAVKRLM S9
UBE2J1 (cow) LTRYLIRSVSVKRLM S9
K17-ac
PAVKRLMkEAAELKD
0 1
UBE2J1 (human) PAVKRLMkEAAELKD K17-ac
UBE2J1 (mouse) PAVKRLMKEAAELKD K17
UBE2J1 (rat) PAVKRLMKEAAELKD K17
UBE2J1 (cow) VSVKRLMKEAAELKD K17
S51-p
TVRGPPDsDFDGGVY
0 1
UBE2J1 (human) TVRGPPDsDFDGGVY S51-p
UBE2J1 (mouse) TVRGPPDSDFDGGVY S51
UBE2J1 (rat) TVRGPPDSDFDGGVY S51
UBE2J1 (cow) TVRGPPDSDFDGGVY S51
K143-ub
ERRALAKkSQDFCCE
0 3
UBE2J1 (human) ERRALAKkSQDFCCE K143-ub
UBE2J1 (mouse) ERRALAKKSQDFCCE K143
UBE2J1 (rat) ERRALAKKSQDFCCE K143
UBE2J1 (cow) ERRALAKKSQDFCCE K143
K164-ub
KDVLLPLkSGSDSSQ
0 3
UBE2J1 (human) KDVLLPLkSGSDSSQ K164-ub
UBE2J1 (mouse) KDVLLPLKSGSGSSQ K164
UBE2J1 (rat) KDVLLPLKSGIDSSQ K164
UBE2J1 (cow) KDILLPLKSGSDSSQ K164
K177-ub
SQADQEAkELARQIs
0 21
UBE2J1 (human) SQADQEAkELARQIs K177-ub
UBE2J1 (mouse) SQADQEAKELARQIs K177
UBE2J1 (rat) SQADQEAKELARQIS K177
UBE2J1 (cow) SQADQEAKELARQIS K177
S184-p
kELARQIsFkAEVNS
Upstream
Downstream
3 65
Effects on Modified Protein
  • enzymatic activity, induced
  • protein degradation
Treatment
  • DTT
  • thapsigargin
  • tunicamycin
UBE2J1 (human) kELARQIsFkAEVNS S184-p
UBE2J1 (mouse) KELARQIsFKAEVNS S184-p
UBE2J1 (rat) KELARQISFKAEVNS S184
UBE2J1 (cow) KELARQISFKAEVNS S184
K186-ub
LARQIsFkAEVNSSG
0 1
UBE2J1 (human) LARQIsFkAEVNSSG K186-ub
UBE2J1 (mouse) LARQIsFKAEVNSSG K186
UBE2J1 (rat) LARQISFKAEVNSSG K186
UBE2J1 (cow) LARQISFKAEVNSSG K186
K194-ub
AEVNSSGkTISESDL
0 1
UBE2J1 (human) AEVNSSGkTISESDL K194-ub
UBE2J1 (mouse) AEVNSSGKTIAESDL K194
UBE2J1 (rat) AEVNSSGKTIAESDL K194
UBE2J1 (cow) AEVNSSGKTIAESDL K194
S251-p
VAKNTSMsPRQRRAQ
0 14
UBE2J1 (human) VAKNTSMsPRQRRAQ S251-p
UBE2J1 (mouse) APKNTSMsPRQRRAQ S251-p
UBE2J1 (rat) gap -
UBE2J1 (cow) VAKSTSMSPRQRRAQ S251
S261
QRRAQQQSQRRLsts
0 1
UBE2J1 (human) QRRAQQQSQRRLsts S261
UBE2J1 (mouse) QRRAQQQsQRRPsts S261-p
UBE2J1 (rat) under review -
UBE2J1 (cow) QRRAQQQSQRRSsTS S261
S266-p
QQSQRRLstsPDVIQ
Upstream
0 72
Treatment
  • EGF
  • ischemia
  • metastatic potential
  • nocodazole
  • SB202190
  • U0126
UBE2J1 (human) QQSQRRLstsPDVIQ S266-p
UBE2J1 (mouse) QQsQRRPstsPDVLQ S266-p
UBE2J1 (rat) gap -
UBE2J1 (cow) QQSQRRSsTSPDVTQ S266-p
T267-p
QSQRRLstsPDVIQG
0 9
UBE2J1 (human) QSQRRLstsPDVIQG T267-p
UBE2J1 (mouse) QsQRRPstsPDVLQG T267-p
UBE2J1 (rat) gap -
UBE2J1 (cow) QSQRRSsTSPDVTQG T267
S268-p
SQRRLstsPDVIQGH
0 11
UBE2J1 (human) SQRRLstsPDVIQGH S268-p
UBE2J1 (mouse) sQRRPstsPDVLQGQ S268-p
UBE2J1 (rat) LQQAHRMAPRIHQEH A228
UBE2J1 (cow) SQRRSsTSPDVTQGQ S268
T282-p
HQPRDNHtDHGGSAV
0 1
UBE2J1 (human) HQPRDNHtDHGGSAV T282-p
UBE2J1 (mouse) QPPRAHHTEHGGSAM T282
UBE2J1 (rat) PRIHQEHPCHNLPSQ P236
UBE2J1 (cow) QQPRDNHTDHGGSAV T282
T295-p
AVLIVILtLALAALI
0 1
UBE2J1 (human) AVLIVILtLALAALI T295-p
UBE2J1 (mouse) AMLIIILTLALAALI T295
UBE2J1 (rat) SQLLRIPP_______ P249
UBE2J1 (cow) AVLIVILTLALAALI T295
Y312-p
RIYLANEyIFDFEL_
0 1
UBE2J1 (human) RIYLANEyIFDFEL_ Y312-p
UBE2J1 (mouse) RIYLANEYIFDFEL_ Y312
UBE2J1 (rat) gap -
UBE2J1 (cow) RIYLANEYIFDFEL_ Y312